Risperdal/Risperdal Consta Indications/Uses

Risperdal: Schizophrenia: RISPERDAL (risperidone) is indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Bipolar Mania: Monotherapy: RISPERDAL is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Adjunctive Therapy: RISPERDAL adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in one short-term trial in adults [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Irritability Associated with Autistic Disorder: RISPERDAL is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. Efficacy was established in 3 short-term trials in children and adolescents (ages 5 to 17 years) [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Risperdal Consta: Schizophrenia: RISPERDAL CONSTA (risperidone) is indicated for the treatment of schizophrenia [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Bipolar Disorder: RISPERDAL CONSTA is indicated as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].